Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for InMed Pharmaceuticals (INM) over the last 1 years, with Sep 2025 value amounting to $60,356.

  • InMed Pharmaceuticals' Gains from Investment Securities fell 67.76% to $60,356 in Q3 2025 from the same period last year, while for Sep 2025 it was $60,356, marking a year-over-year decrease of 94.77%. This contributed to the annual value of $61,410 for FY2025, which is 82.11% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $60,356 for Q3 2025, which was down 67.76% from $187,223 recorded in Q3 2024.
  • InMed Pharmaceuticals' 5-year Gains from Investment Securities high stood at $971,494 for Q4 2023, and its period low was -$12,307 during Q4 2022.
  • For the 3-year period, InMed Pharmaceuticals' Gains from Investment Securities averaged around $330,302, with its median value being $144,678 (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 7,993.83% in 2023, then slumped by 67.76% in 2025.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Gains from Investment Securities stood at -$6,030 in 2021, then skyrocketed by 212.77% to -$12,307 in 2022, then surged by 7,993.83% to $971,494 in 2023, then surged by 83.31% to $187,223 in 2024, then slumped by 67.76% to $60,356 in 2025.
  • Its Gains from Investment Securities was $60,356 in Q3 2025, compared to $187,223 in Q3 2024 and $971,494 in Q4 2023.